EMA Clarifies Endpoints for Adult, Pediatric Acute Heart Failure Trials

Clinical Trials Advisor
The European Medicines Agency last month released final guidance on the primary and secondary endpoints sponsors should use to evaluate drugs to treat acute heart failure — along with recommendations on designing and conducting such studies in children.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00